Abstract
Real-world data encompass data primarily captured for the provision or operation of services, for example, electronic health records for direct care purposes, but which may have secondary uses for informing research or commissioning. Public benefit is potentially forfeited by the underutilisation of real-world data for secondary uses, in part due to risk aversion when faced with the prospect of navigating necessary and important data governance processes. Such processes can be perceived as complex, daunting, time-consuming and exposing organisations to risk. By providing an overview description and discussion around the role of six key legal and information governance frameworks and their role regarding responsible data access, linkage and sharing, our intention is to make data governance a less daunting prospect and reduce the perception that it is a barrier to secondary uses, thus enabling public benefit.
Funder
Public Health Research Programme
Reference44 articles.
1. U.S. Food and Drug Administration (FDA) . Real-world evidence: U.S. food and Drug Administration (FDA). 2022. Available: https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence
2. Joore M , Grimm S , Boonen A , et al . Health technology assessment: a framework. RMD Open 2020;6:e001289. doi:10.1136/rmdopen-2020-001289
3. Observational and Interventional study design types; an overview;Thiese;Biochem Med (Zagreb),2014
4. National Institute for Health and Care Excellence (NICE) . NICE real-world evidence framework: National Institute for health and care excellence. NICE, 2022. Available: https://www.nice.org.uk/corporate/ecd9/chapter/overview
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献